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WIF1 prevents Wnt5A mediated LIMK/CFL
phosphorylation and adherens junction
disruption in human vascular endothelial
cells
Tom Skaria1, Esther Bachli2 and Gabriele Schoedon1*
Abstract
Background: Wnt5A is released by activated macrophages and elevated levels have been detected in sepsis
patients with severe systemic inflammation. However, the signalling and functional effects of Wnt5A in the vascular
endothelial cells (VEC) remained unclear. Recently, we showed that Wnt5A affects barrier function in human VEC
through Ryk interaction. Wnt5A/Ryk signalling activates LIMK to inactivate the actin depolymerisation factor CFL by
phosphorylation, promotes actin polymerisation and disrupts endothelial adherens junctions.
Findings: Here, we investigate the antagonistic effect of the Ryk specific secreted Wnt antagonist Wnt inhibitory
factor (WIF)-1 on Wnt5A-mediated activation/inactivation of LIMK/CFL, and adherens junction disruption in human
VEC. In human coronary artery endothelial cells (HCAEC), treatment with Wnt5A enhanced the phosphorylation of
LIMK and CFL that was significantly prevented by WIF1. The presence of WIF1 suppressed Wnt5A-mediated
disruption of β-catenin and VE-cadherin adherens junctions in HCAEC, thereby preventing barrier dysfunction
caused by Wnt5A.
Conclusion: We conclude that WIF1 or molecules with similar properties could be potent tools for the prevention
of vascular leakage due to Wnt5A-mediated actin cytoskeleton remodeling in diseases associated with systemic
inflammation.
Keywords: Inflammation, Endothelial permeability, Wnt5A, WIF1, Ryk, Cytoskeleton remodeling
Background
Vascular endothelial cells (VEC) in physiologic state play
a crucial role in maintaining vascular homeostasis. They
preserve blood fluidity [1, 2], control blood pressure,
prevent the adherence of leukocytes [1] and platelets [2],
and regulate vascular permeability [1]. In diseases associ-
ated with inflammatory states, vascular leakage is a major
pathophysiologic event. In systemic inflammation and
sepsis, as well as in autoimmune and allergic inflamma-
tion, activated blood components and inflammatory medi-
ators such as cytokines act upon VEC and heavily alter
their functions [2], conferring an inflamed phenotype.
Inflamed VEC are procoagulant and exhibit increased
production of vasoactive substances, expression of cell
adhesion molecules, synthesis of inflammatory mediators
including chemoattractants, and barrier dysfunction caus-
ing leakage [1].
Wnt5A, a lipid modified signalling protein of the non-
canonical Wnt family [3] is detected in high levels in
sera and bone marrow of patients with severe systemic
inflammation and septic shock [4, 5]. Its expression has
also been found elevated in macrophage-accumulated in-
tima from human and murine atherosclerotic lesions [6].
Wnt5A is a chemokine secreted by Toll-like receptor-
activated human macrophages, and is crucially involved in
sustaining their inflammatory response [4, 7]. However,
the targets and functional effects of Wnt5A on human
VEC remained unclear.
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Recently, we identified a novel Wnt5A signalling mech-
anism affecting monolayer integrity and barrier function
[8] in our established in vitro system of primary immuno-
competent VEC, human coronary artery endothelial cells
(HCAEC) [9]. Wnt5A targets the Rho-associated protein
serine/threonine kinase (ROCK) to phosphorylate LIMK2
and actin depolymerisation factor CFL1, thereby increas-
ing actin stress fiber formation. This disrupts β-catenin
and VE-cadherin at adherens junctions (AJ) leading to
inter-endothelial gap formation and enhanced endothelial
monolayer permeability. To mediate its effects on endo-
thelial barrier function, Wnt5A has been found to act
through Ryk receptor as silencing Ryk expression pre-
vented Wnt5A-induced hyperpermeability [8]. Antagonis-
ing Wnt5A activity with Ryk specific Wnt inhibitory
factor (WIF) -1 [10] prevents Wnt5A-induced actin stress
fiber formation [8, 11] while Fzd or Ror specific secreted
Frizzled-related peptide (sFRP) [10] is ineffective [8, 11].
However, the ability of the natural Wnt antagonists
sFRP1 and WIF1 to antagonize LIMK/CFL phosphoryl-
ation and AJ disruption, the cellular events occurring up-
stream and downstream of enhanced actin stress fiber
formation upon Wnt5A treatment in HCAEC need to be
still verified. Here, we investigated the effects of sFRP1
and WIF1 on the phosphorylation of LIMK and CFL in
human coronary artery endothelial cells (HCAEC) in the
presence of Wnt5A.
Methods
Cell culture
HCAEC (Cat. No. CC-2585, Clonetics, Lonza, Switzerland)
were propagated in EBM-2 medium (Clonetics, Lonza)
supplemented with EGM-2MV Single Quots with 5% FBS
(Clonetics, Lonza) [9]. HCAEC used in this study were
tested positively and functionally for CD31/105, von
Willebrand Factor VIII, and acetylated low density lipopro-
tein uptake as certified by the manufacturer (Lonza).
Additionally, we confirmed stable CD31 expression by
HCAEC under experimental conditions (Additional file 1:
Figure S1). Cells were treated with recombinant human/
mouse Wnt5A (250 ng/mL, R&D systems), recombinant
human WIF1 (15 μg/mL, R&D systems) or recombinant
human sFRP1 (10 μg/mL, R&D systems) [8]. Experiments
were performed using cells from passages 3–6.
Immunoblotting
Immunoblotting of pLIMK, LIMK, pCFL and CFL and
quantification of band densities were performed as de-
scribed [11]. The following primary antibodies were used
with dilutions indicated: rabbit anti-phospho LIMK2,
polyclonal (1:500, Abcam), rabbit anti-LIMK2, polyclonal
(1:1000, ThermoFischer Scientific), rabbit anti-phospho
CFL, polyclonal (1:1000, Abcam), rabbit anti- CFL, poly-
clonal (1:1000, Abcam). Anti-rabbit IgG- HRP-linked
whole antibody (GE Healthcare UK Limited) was used as
the secondary antibody, diluted 1:5000.
Immunofluorescence staining
Immunofluorescence staining for β-catenin and VE-
cadherin were performed as described [8]. The following
primary antibodies were used with dilutions indicated:
rabbit-anti- β-catenin (1:150, Cell Signalling Technology),
rabbit-anti-VE-cadherin (1:100, Cell Signalling Technol-
ogy), rabbit-anti-CD31 (1:40, Epitomics). Alexa 568 la-
belled goat anti-rabbit antibody was used as the secondary
antibody, diluted 1:2000. The cellular fluorescence inten-
sities of β-catenin and VE-cadherin at inter-cellular
boarders were quantified from five different fields (cover-
ing approx. 90% of total cells/field) using ImageJ based Fiji
Fig. 1 Effects of the Wnt antagonists WIF1 and sFRP1 on Wnt5A-mediated phosphorylation of LIMK and CFL in VEC. Immunoblot of (a) pLIMK,
LIMK and (b) pCFL and CFL in HCAEC treated with Wnt5A alone and in combination with either WIF1 or sFRP1 (sFRP) for 1 and 4 h, respectively.
Bands from left to right, non-treated cells; Wnt5A-treated cells; Wnt5A + sFRP1 treated cells; Wnt5A +WIF1 treated cells. The ratios of (a) pLIMK2/
LIMK2, and (b) pCFL/CFL were calculated from densitometry analyses. Data are mean ± SEM from three independent experiments. *P < 0.05 vs
non-treated, **P < 0.05 vs Wnt5A
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software (Fiji is Just ImageJ) and corrected for background
fluorescence.
Statistical analysis
Data were analysed using GraphPad Prism software version
5.04 (GraphPad Software, San Diego, CA). An unpaired 2-
tailed Student’s t-test or for comparing data among groups,
1-way ANOVA followed by the Newman-Keuls test
was used and differences were considered statistically
significant at P < 0.05.
Results and discussion
Phosphorylation of LIMK/CFL were significantly increased
in Wnt5A-treated HCAEC compared with non-treated
cells (Fig. 1), thereby confirming previous findings [8].
Here, we further tested the antagonizing effects of WIF1
on Wnt5A-induced phosphorylation of LIMK/CFL. As
shown herein by western blot analysis, combining Wnt5A
with WIF1 significantly suppressed Wnt5A-triggered
phosphorylation of both LIMK and CFL while combin-
ation with sFRP was not effective (Fig. 1). When activated
by phosphorylation, LIMK phosphorylates the actin de-
polymerisation factor CFL1. Phosphorylation inactivates
CFL1 and prevents its ability to depolymerise actin
filaments leading to the formation of actin stress fibers. In-
creased stress fiber formation disrupts the AJ assembly at
inter-endothelial junctions [12]. Here, we further investi-
gated the antagonizing effects of WIF1 on Wnt5A-induced
disruption of AJ. In non-treated cells, β-catenin and VE-
cadherin were aligned at the cellular periphery forming
intercellular boarders. Consistent with our previous finding
[8], treatment with Wnt5A notably disrupted both β-
catenin and VE-cadherin at intercellular boarders, forming
large inter-endothelial gaps (Fig. 2, white arrow heads).
Additionally, this study has shown that combining Wnt5A
with WIF1 notably prevented Wnt5A-induced disassembly
of both β-catenin and VE-cadherin while sFRP failed to
exert any antagonistic effects (Fig. 2, Additional file 2:
Figure S2A, B). This finding is supported by functional
measurements of HCAEC monolayer permeability. Treat-
ment with Wnt5A significantly decreased the resistance of
HCAEC monolayers to alternating current, thereby indi-
cating enhanced permeability of Wnt5A-treated HCAEC
monolayers (Additional file 3: Figure S3), confirming
previous findings [8]. Combining Wnt5A with WIF1
significantly prevented Wnt5A-induced endothelial hyper-
permeability while no significant antagonistic effect was
observed with sFRP1 (Additional file 3: Figure S3).
Ryk was previously identified as the Wnt5A receptor
on HCAEC [8]. The current study demonstrates the
potency of WIF1 to prevent Wnt5A-induced cytoskeleton
remodelling and monolayer barrier dysfunction in human
vascular endothelial cells. WIF1 is a 371 amino acid pro-
tein composed of a distinct WIF domain homologous to
the Wnt binding WIF domain of the Ryk receptor, five
EGF-like domains, and a hydrophilic tail [13]. Secreted
Wnt antagonists including WIF1 and sFRP sequester Wnt
proteins away from the receptors, thereby inhibiting sig-
nalling pathways [10, 13] (see Scheme, Fig. 3). It has been
shown that the antagonistic effect of WIF1 is mainly medi-
ated by its WIF domain. In an attempt to map the Wnt
binding sites in WIF domain, previous studies revealed the
presence of an alkyl-binding site that is capable of interact-
ing with essential lipid groups of Wnts [14–16]. Although
WIF1 is expressed in different tissues, higher levels are
reported in cartilage, lung, retina and brain [13, 17–20].
Several studies link elevated expression level of Wnt5A
Fig. 2 AJ assembly in VEC treated with Wnt5A in the presence or
absence of WIF1 and sFRP1. Immunofluorescence staining for β-
catenin and VE-cadherin (red) in HCAEC treated with Wnt5A either
alone or in the presence of WIF1 and sFRP1 for 8 h. Blue stain (DAPI)
indicates nuclei. Arrow heads point to inter-endothelial gaps. Zeiss
Axioskope, original magnification 630 ×
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to inflammatory response in sepsis and atherosclerosis
[4–6, 21]. Inflammatory activated leucocytes are the
major source of Wnt5A [4, 7] and in this context, the
observation that elevated Wnt5A levels correlate posi-
tively with the leucocyte count in sepsis is of particular
interest [5]. The presence of lower levels of sFRP observed
during worsening of disease in sepsis patients [5] is of fur-
ther interest as various sFRP are shown to attenuate Fzd
receptor-mediated inflammatory Wnt5A signalling in leu-
cocytes [4, 7]. A previous study showed the upregulation
of WIF1 mRNA in pro-inflammatory activated human
monocytes [4]. Presently, it is not clear if monocytes re-
lease WIF1 to counter regulate the adverse effects of
Wnt5A on VEC. In light of recent in vitro findings sup-
porting an inhibitory effect of WIF1 on Wnt5A signalling
in human VEC, the altered expression and antagonistic ef-
fects of WIF1 in diseases showing dysregulated Wnt5A
signalling is worthy of future investigations.
In conclusion, this is the first report identifying antagon-
istic effects of WIF1 on Wnt5A mediated actin cytoskeleton
A
B
C
Fig. 3 Interaction of antagonists with Wnt5A/Ryk signalling in vascular endothelial cells. a Wnt5A binds to the Ryk receptor by interaction with its
WIF domain, inducing downstream activation of the ROCK/LIMK/CFL pathway. Phosphorylated CFL is inactivated and allows formation of actin stress
fibers (f-actin), that can interact with adherens junction protein β-catenin and tears VE-cadherin junctions apart. As a result, endothelial monolayer
permeability is increased. b In the presence of the Wnt antagonist secreted Frizzled-related peptide (sFRP) that covers the Wnt5A binding site for the
cysteine-rich domain of Frizzled receptors, interaction of Wnt5A with Ryk is still unaffected. c In the presence of the Wnt antagonist WIF1 (WIF) that
covers the Wnt5A binding site interacting with Ryk receptor’s WIF domain, Wnt5A/Ryk interaction is blocked, and downstream signalling
is not transduced. CFL1 remains active and restricts f-actin formation. Actin remains mainly in the globular form (g-actin), that does not
interact with adherens junction proteins
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signalling pathway in primary human vascular endothelial
cells. Our data suggest that the Wnt5A pathway leading to
barrier dysfunction of vascular endothelial cells is a target
for the natural Wnt5A antagonist WIF1. This finding could
offer novel therapeutic options for diseases associated with
severe vascular leakage such as sepsis and septic shock.
Additional files
Additional file 1: Figure S1. Expression of CD31 in HCAEC.
Immunofluorescence staining for CD31 protein (red) in HCAEC either
untreated (none) or treated with Wnt5A or TNF-alpha (20 U/mL) for 8 h.
Nuclei are stained blue (DAPI). Zeiss Axioskope, original magnification
630 × . (PDF 8535 kb)
Additional file 2: Figure S2. β-catenin and VE-cadherin expression at
inter-cellular boarders. Mean fluorescence intensities of (a) β-catenin and
(b) VE-cadherin at inter-cellular boarders quantified using ImageJ based
Fiji software. Data are mean ± SEM from three independent experiments.
*P < 0.05 vs non-treated, **P < 0.05 vs Wnt5A. (ZIP 1032 kb)
Additional file 3: Figure S3. Barrier function of Wnt5A-treated VEC in
the presence or absence of WIF1 and sFRP1. a ECIS assisted measurements
(Additional file 4: supplementary methods) showing resistance of HCAEC
monolayers grown in 8W10E+ arrays treated with vehicle (black), Wnt5A
(green), Wnt5A +WIF1 (yellow) and Wnt5A + sFRP1 (purple). Data shown are
the resistance measurements conducted at 4000 Hz and are mean ± SEM of
2 wells from 1 out of three representative experiments. b Barrier function
measurements indicating the significance of WIF1’s antagonistic effect on
Wnt5A and are mean ± SEM of three independent experiments run with
duplicate wells. *P < 0.05 vs non-treated, **P < 0.05 vs Wnt5A. (PDF 2125 kb)
Additional file 4: Supplementary methods. (PDF 300 kb)
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